- Title: Subtitle
- Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
- Creators
- Jeffrey L Wolf - 1University of California, San Francisco, San Francisco, CA, USADavid Siegel - 2Hackensack University Medical Center, Hackensack, NJ, USAHartmut Goldschmidt - 3University of Heidelberg, Heidelberg, GermanyKatharine Hazell - 4Novartis Pharma AG, Basel, SwitzerlandPriscille M Bourquelot - 4Novartis Pharma AG, Basel, SwitzerlandBourras R Bengoudifa - 4Novartis Pharma AG, Basel, SwitzerlandJeffrey Matous - 5Colorado Blood Cancer Institute, Denver, CO, USARavi Vij - 6Washington University, St. Louis, MO, USAMargarida de Magalhaes-Silverman - 7University of Iowa, Iowa City, IA, USARafat Abonour - 8Indiana University Cancer Center, Indianapolis, IN, USAKenneth C Anderson - 9Dana-Farber Cancer Institute, Boston, MA, USASagar Lonial - 10Emory University, Atlanta, GA, USA
- Resource Type
- Letter/Communication
- Publication Details
- Leukemia & lymphoma, Vol.53(9), pp.1820-1823
- Publisher
- Informa Healthcare
- DOI
- 10.3109/10428194.2012.661175
- PMID
- 22288662
- ISSN
- 1042-8194
- eISSN
- 1029-2403
- Language
- English
- Date published
- 09/2012
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094377802771
Letter/Communication
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
Leukemia & lymphoma, Vol.53(9), pp.1820-1823
09/2012
DOI: 10.3109/10428194.2012.661175
PMID: 22288662
Details
Metrics
17 Record Views